Atlas Trials

A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate to Severe Refractory Autoimmune Diseases

Clinical trial NCT07614191 · RECRUITING

Trial details

NCT number
NCT07614191
Sponsor
Vivacta Biotechnology (Shanghai) Co., Ltd.
Status
RECRUITING
Phase
Early Phase 1
Study type
INTERVENTIONAL
Moderate to Severe Refractory Autoimmune Diseases
Start date
2026-05-25
Primary completion
2031-12-30
Enrollment
22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.